-
2024-514791-40-00
9
2016-08-03
pediatric cancer
-
2023-509152-33-00
4
2016-07-25
Advanced solid tumor
-
2024-512222-28-00
10
2015-06-02
Newly diagnosed with an intracranial or spinal ependymoma (all WHO gra
-
2024-516078-31-00
10
2015-05-05
Recurrent and Primary Refractory Ewing Sarcoma
-
2022-501257-36-00
9
2015-03-19
Treatment of advanced melanoma, or advanced, relapsed or
refractory PD
-
2024-518254-16-00
5
2013-03-01
Acute Myeloid Leukemia (Pediatric 0-18 years)
-
2025-521067-13-00
5
2026-04-24
Atherosclerotic Cardiovascular Disease (ASCVD)
-
2023-503684-42-00
4
2026-02-20
Neuroblastoma
-
2025-521681-10-00
4
2025-10-02
Lung Cancer
-
2024-519746-70-01
4
2025-09-15
Sickle Cell Disease
-
2025-520520-17-00
5
2025-09-05
Heterozygous familial hypercholesterolaemia
-
2024-516473-72-00
5
2025-07-31
Multifocal Motor Neuropathy
-
2023-504909-37-00
9
2025-07-03
Cystic fibrosis
-
2024-516815-26-00
5
2025-05-30
Chronic rhinosinusitis with nasal polyps
-
2023-506842-22-00
7
2025-05-19
Recurrent endometrial cancer, recurrent epithelial ovarian, fallopian
-
2024-513210-36-00
5
2025-04-04
Chronic Spontaneous Urticaria
-
2024-512998-27-00
5
2025-02-21
Non-Small Cell Lung Cancer
-
2024-511565-11-00
9
2025-02-12
Myelofibrosis
-
2024-518343-38-00
5
2025-02-12
Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with C
-
2023-505394-32-00
5
2025-02-06
chronic graft versus host disease
-
2024-518669-83-00
4
2024-12-05
acute promyelocytic leukemia (APL) in children and adolescents
-
2024-518769-80-00
6
2024-11-25
HAMLETT compares regular treatment guidelines for patients in remissio
-
2024-516511-24-00
11
2024-11-14
Chronic myeloid leukaemia
-
2024-510581-17-00
4
2024-11-05
Adult subjects with New York Heart Association (NYHA) Class III conges